Abstract
Ruthenium seems to be a promising alternative to platinum because of the wide range of oxidation states it has and its ability to form complexes with bioactive ligands. In this study, naringin, a naturally occurring flavonoid, was used to synthesize a novel ruthenium complex with potential anticancer activity. The characterization of the synthesized complex was done by UV–Vis spectroscopy, FTIR and NMR studies. In addition, the complex was tested against Human A549 cell lines to determine the anticancer effect, and against human dermal fibroblasts (HDFa) to find any underlying toxicity. Further, the morphological changes of the cancer cells can be determined by using bio-atomic force microscopy. Results showed that the synthesized complex was able to induce anticancer effects against A549 with minimal impact to HDFa. In this study, we investigated the anticancer properties of naringin-ruthenium (II) complex using live- and dead-cell staining assay, MTT, Trypan blue, and lactate dehydrogenase assay. Further, morphological changes were observed in the A549 cells using Bio-AFM. The Bio-AFM results have proven the better cytotoxic behavior of naringin-ruthenium (II) complex. The cell viability results also provided the anticancer efficacy of the complex.
This is a preview of subscription content, log in via an institution to check access.
References
Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD (2014) Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 5:404–417
Camargo CA, Gomes-Marcondes MC, Wutzki NC, Aoyama H (2012) Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma. Anticancer Res 32:129–134
Chen R, Qi QL, Wang MT, Li QY (2016) Therapeutic potential of naringin: an overview. Pharm Biol 54:3203–3210
Ijaz S, Akhtar N, Khan MS, Hameed A, Irfan M, Arshad MA, Ali S, Asrar M (2018) Plant derived anticancer agents: A green approach towards skin cancers. Biomed Pharmacother 103:1643–1651
Jayakumar T, Hsu CY, Khamrang T, Hsia CH, Hsia CW, Manubolu M, Sheu JR (2018) Possible molecular targets of novel ruthenium complexes in antiplatelet therapy. Int J Mol Sci 19:1818
Jovanovic KK, Gligorijevic N, Gaur R, Mishra L, Radulovic S (2016) Anticancer activity of two ruthenium(II)-DMSO-chalcone complexes: comparison of cytotoxic, pro-apoptotic and antimetastatic potential. J BUON 21:482–490
León IE, Cadavid-Vargas JF, Resasco A, Maschi F, Ayala MA, Carbone C, Etcheverry SB (2016) In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice. J Biol Inorg Chem 21:1009–1020
Li H, Yang B, Huang J, Xiang T, Yin X, Wan J, Luo F, Zhang L, Li H, Ren G (2013) Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting—catenin signaling pathway. Toxicol Lett 220:219–228
Popolin CP, Reis JPB, Becceneri AB, Graminha AE, Almeida MAP, Corrêa RS, Colina-Vegas LA, Ellena J, Batista AA, Cominetti MR (2017) Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. PLoS One 12:e0183275
Raza A, Xu X, Xia L, Xia C, Tang J, Ouyang Z (2016) Quercetin-iron complex: synthesis, characterization, antioxidant, DNA binding, DNA cleavage, and antibacterial activity studies. J Fluoresc 26:2023–2031
Roy S, Das R, Ghosh B, Chakraborty T (2018) Deciphering the biochemical and molecular mechanism underlying the in vitro and in vivo chemotherapeutic efficacy of ruthenium quercetin complex in colon cancer. Mol Carcinog 57:700–772
Shao M, Gang J, Kim S, Yoon M (2016) A new kaempferol-based Ru(II) coordination complex, Ru(kaem)Cl(DMSO)3: structure and absorption–emission spectroscopy study. Bull Korean Chem Soc 37:1625–1631
Thangavel P, Viswanath B, Kim S (2017) Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors. Int J Nanomed 12:2749–2758
Thangavel P, Viswanath B, Kim S (2018) Synthesis and characterization of kaempferol-based ruthenium (II) complex: a facile approach for superior anticancer application. Mater Sci Eng C Mater Biol Appl 89:87–94
Yang X, Chen L, Liu Y, Yang Y, Chen T, Zheng W, Liu J, He QY (2012) Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway. Biochimie 94:345–353
Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu F, Feng J, Shen J, Wei B (2014) Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NF-κB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. Int J Oncol 45:1929–1936
Zeng L, Gupta P, Chen Y, Wang E, Ji L, Chao H, Chen ZS (2017) The development of anticancer ruthenium (II) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev 46:5771–5804
Acknowledgements
This research was supported by the R&D Program for Society of the National Research Foundation (NRF) funded by the Ministry of Science and ICT of Korea (2015M3A9E2031372).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial interests.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Garcia, J.P., Lakshmi, B.A. & Kim, S. Potential anticancer applications of the novel naringin-based ruthenium (II) complex. 3 Biotech 9, 181 (2019). https://doi.org/10.1007/s13205-019-1718-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-019-1718-4